Ross Moat - 04 Sep 2025 Form 4 Insider Report for Kiniksa Pharmaceuticals International, plc (KNSA)

Signature
/s/ Aaron Young, Attorney-in-Fact
Issuer symbol
KNSA
Transactions as of
04 Sep 2025
Net transactions value
-$124,397
Form type
4
Filing time
08 Sep 2025, 16:37:48 UTC
Previous filing
03 Sep 2025

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Moat Ross CHIEF CORP. & COMM. OFFICER 23 OLD BOND STREET, THIRD FLOOR, LONDON, UNITED KINGDOM /s/ Aaron Young, Attorney-in-Fact 08 Sep 2025 0001857177

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KNSA Class A Ordinary Share Sale $124,397 -3,523 -27% $35.31 9,415 04 Sep 2025 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on November 13, 2024.